Experimental and Clinical Evidence of Endothelial Dysfunction in Inflammatory Bowel Disease

Mariana Ferreira-Duarte; Joana Beatriz Sousa; Carmen Diniz; Teresa Sousa; Margarida Duarte-Araújo; Manuela Morato

doi:10.2174/1381612826666200701212414

Experimental and Clinical Evidence of Endothelial Dysfunction in Inflammatory Bowel Disease

Curr Pharm Des. 2020;26(30):3733-3747. doi: 10.2174/1381612826666200701212414.

Authors

Mariana Ferreira-Duarte¹, Joana Beatriz Sousa¹, Carmen Diniz¹, Teresa Sousa², Margarida Duarte-Araújo¹, Manuela Morato¹

Affiliations

¹ LAQV@REQUIMTE, University of Porto, Porto, Portugal.
² Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.

PMID: 32611296
DOI: 10.2174/1381612826666200701212414

Abstract

The endothelium has a crucial role in proper hemodynamics. Inflammatory bowel disease (IBD) is mainly a chronic inflammatory condition of the gastrointestinal tract. However, considerable evidence points to high cardiovascular risk in patients with IBD. This review positions the basic mechanisms of endothelial dysfunction in the IBD setting (both clinical and experimental). Furthermore, we review the main effects of drugs used to treat IBD in endothelial (dys)function. Moreover, we leave challenging points for enlarging the therapeutic arsenal for IBD with new or repurposed drugs that target endothelial dysfunction besides inflammation.

Keywords: IBD; Inflammatory Bowel Disease; cardiovascular; endothelium dysfunction; experimental and clinical studies; hemodynamics.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Colitis*
Humans
Inflammation / drug therapy
Inflammatory Bowel Diseases* / drug therapy
Vascular Diseases*